Trial of Varenicline and Financial Incentives to Help Adults Who Use Both E-cigarettes and Cannabis Quit Vaping

What this Trial Is About

This research aims to better understand outcomes of quitting e-cigarettes in adults who also use cannabis. It focuses on how cannabis and tobacco interact during quitting attempts using varenicline, a medication approved for cigarette cessation but not for e-cigarette cessation. The study targets adults aged 18 to 40 who use both e-cigarettes and cannabis, regardless of their interest in quitting cannabis. The trial is conducted at three sites in South Carolina. Participants receive a 12-week treatment with varenicline following a standard dose schedule starting from 0.5 mg once daily and increasing to 1.0 mg twice daily, maintained for 11 weeks. Alongside medication, participants receive psychosocial counseling and financial incentives each week based on verified abstinence from e-cigarettes using urinary cotinine tests. This approach combines medication, behavioral support, and incentives. During the study, participants will attend weekly visits for assessments including urine tests to confirm tobacco abstinence and cannabis use. Researchers will track changes in cannabis use during the treatment and evaluate the impact of cannabis use severity on quitting success. The main outcome measured is 7-day tobacco abstinence at the end of 12 weeks. The total study duration per participant is 12 weeks, with monitoring throughout this period.

E-cigarette Cessation in Adults Who Co-use Cannabis